Dapazin 5 mg (Tablet)

Indications

• Adjunct to diet and exercise
• Improves glycemic control
• For adults with type 2 diabetes mellitus

Pharmacology

• Inhibitor of Sodium-glucose co-transporter 2 (SGLT2)
• Reduces reabsorption of filtered glucose
• Increases urinary glucose excretion

Dosage & Administration

• Recommended starting dose of 5 mg once daily
• Can be increased to 10 mg once daily
• Assessment of renal function recommended prior to initiation
• No established safety and efficacy in children and adolescents

Interaction

• May interact with diuretics, insulin, antihypertensives, pioglitazone, etc.

Contraindications

• Known hypersensitivity to Dapagliflozin or excipients
• Severe renal impairment
• End-stage renal diseases or patients on dialysis

Side Effects

• Hypotension
• Ketoacidosis
• Acute kidney injury
• Impairment in renal function
• Genital mycotic infections
• Increases in low-density lipoprotein cholesterol (LDL-C)
• Bladder cancer
• Hypoglycemia with concomitant use with insulin and insulin secretagogues
• Urinary tract infection

Pregnancy & Lactation

• Pregnancy category C
• Use during pregnancy only if potential benefit justifies potential risk to the fetus
• Not to be used during lactation

Precautions & Warnings

• Assess volume status and correct hypovolemia before initiating
• Monitor renal function during therapy
• Consider a lower dose of insulin or the insulin secretagogue to reduce the risk of hypoglycemia
• Should not be used in patients with active bladder cancer
• No conclusive evidence of macrovascular risk reduction

Therapeutic Class

• Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors

Storage Conditions

• Store below 30°C
• Keep away from light
• Keep away from the reach of children

Related Brands

• Dapaglip 5 mg (Tablet) - incepta-pharmaceuticals-ltd